A Phase II Study of Chloroquinoxaline Sulfonamide (CQS) in Colorectal Cancer Stage IV
OBJECTIVES: I. Assess the antitumor activity and toxicities of chloroquinoxaline sulfonamide
in patients with stage IV colorectal cancer.
OUTLINE: This is a multicenter study. Patients receive chloroquinoxaline sulfonamide IV over
1 hour weekly for 4 consecutive weeks. Treatment continues every 6 weeks in the absence of
disease progression or unacceptable toxicity. Patients are followed for at least 30 days.
PROJECTED ACCRUAL: A total of 16-25 patients will be accrued for this study within 8 months.
Interventional
Primary Purpose: Treatment
Eric H. Kraut, MD
Study Chair
Ohio State University Comprehensive Cancer Center
United States: Federal Government
CDR0000067896
NCT00005864
April 2000
February 2004
Name | Location |
---|---|
University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan 48109-0752 |
Arthur G. James Cancer Hospital - Ohio State University | Columbus, Ohio 43210 |
Cleveland Clinic Taussig Cancer Center | Cleveland, Ohio 44195 |
Central Baptist Hospital | Lexington, Kentucky 40503 |